Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3251-3256

  Pijpe, J ^a   Meijer, J M ^a   Bootsma, H ^a   Van Der Wal, J E ^a   Spijkervet, F K L ^a   Kallenberg, C G M ^a   Vissink, A ^a   Ihrler, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD79A ANTIGEN; CYTOKERATIN 14; KI 67 ANTIGEN; RITUXIMAB; SODIUM;

ADIPOSE TISSUE; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; LYMPH VESSEL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALIVATION; SJOEGREN SYNDROME; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOPSY; CELL PROLIFERATION; FEMALE; HUMANS; MIDDLE AGED; PAROTID GLAND; SALIVA; SALIVARY GLANDS; SJOGREN'S SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350558490     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24903     Document Type: Article

References (16)

1. Meijer JM, Pijpe J, Bootsma H, Vissink A, Kallenberg CG. The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol 2007;32:292-297 (Pubitemid 350242575)
2. Edwards JC, Cambridge G. B cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
3. Ihrler S, Zietz C, Sendelhofert A, Riederer A, Lohrs U. Lymphoepithelial duct lesions in Sjögren-type sialadenitis. Virchows Arch 1999;434:315-323 (Pubitemid 29201834)
4. Ihrler S, Zietz C, Sendelhofert A, Lang S, Blasenbreu-Vogt S, Lohrs U. A morphogenetic concept of salivary duct regeneration and metaplasia. Virchows Arch 2002;440:519-526 (Pubitemid 34591736)
5. Ihrler S, Blasenbreu-Vogt S, Sendelhofert A, Rossle M, Harrison JD, Lohrs U. Regeneration in chronic sialadenitis: an analysis of proliferation and apoptosis based on double immunohistochemical labelling. Virchows Arch 2004;444:356-361 (Pubitemid 38553641)
6. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-2750 (Pubitemid 41369102)
7. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005;64:958-960 (Pubitemid 40733928)
8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558
9. Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007;46:335-341 (Pubitemid 46189797)
10. Baum BJ. Principles of saliva secretion. Ann N Y Acad Sci 1993;694:17-23.
11. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008;68:554-564
12. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-778 (Pubitemid 46399424)
13. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25.
14. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-1477 (Pubitemid 46764075)
15. Palmer RM, Eveson JW, Gusterson BA. Epimyoepithelial islands in lymphoepithelial lesions: an immunocytochemical study. Virchows Arch A Pathol Anat Histopathol 1986;408:603-609
16. Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? Arthritis Rheum 2005;52:2984-2995